Why Lexicon Pharmaceuticals Inc. Stock Briefly Shot Higher

Lexicon shares zoom higher after announcing a beneficial study collaboration before the opening bell. Find out what this means for shareholders.

Jul 9, 2014 at 1:26PM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX), a biopharmaceutical company focused on developing therapies to combat chronic diseases, briefly roared higher this morning by as much as 22% after announcing a collaboration with non-profit group JDRF to run a randomized phase 2 study involving Lexicon's investigational compound LX4211 in a younger population with type 1 diabetes. Shares have since cooled and up are less than 4% as of this writing.

So what: According to the details of this morning's announced collaboration, JDRF will provide the funding for this midstage study with the two aiming to enroll up to 76 individuals below the age of 30 and with an HbA1c level of 9% or greater. The trial will last 12 weeks and patients will be randomly assigned to receive either a 400 mg dose of LX4211 or the placebo. The primary endpoint will evaluate the efficacy and potential superiority of LX4211 compared to the placebo, with secondary endpoints comprised of measuring variability in blood sugar levels and overall patient insulin dependence.

Now what: The big key to this morning's collaboration, and why Lexicon briefly took off, is the fact that JDRF is picking up the tab on this study. With no money out of pocket for Lexicon it can simply show off its next-generation diabetes drug which is a dual SGLT1 and SGLT2 inhibitor.

Rather than working via the liver or pancreas like previous FDA-approved medications, LX4211 regulates blood sugar via the SGLT1 in the small intestine and SGLT2 in the kidneys. There are already two SGLT2 inhibitors approved by the Food and Drug Administration -- Johnson & Johnson's Invokana and AstraZeneca's Farxiga -- but the thinking here is that doubling up and focusing on inhibition of both SGLT1 and SGLT2 could deliver superior results. I'll certainly need to see LX4211 in a considerably larger study than a few dozen people before I'd give it two thumbs up, but its initial phase 2 data in both type 1 and type 2 diabetes has been intriguing enough to merit a steady spot on my watchlist.

LX4211 may offer loads of potential, but the enormous growth prospects of this revolutionary product could leave LX4211 eating dust! 
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool owns shares of, and recommends Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers